K Pyörälä, CM Ballantyne, B Gumbiner, MW Lee, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Over the 5.4-year median follow-up period, simvastatin produced similar changes
in serum lipid levels in 893 patients with the metabolic syndrome and in 3,040 patients without
the metabolic syndrome. The relative risks of main end points in simvastatin-treated ... Cited by 80 - Related articles - BL Direct - All 8 versions
K PY, CM BALLANTYNE, B GUMBINER, MW LEE, A … - Diabetes Care, 2004 - meditrina.gr OBJECTIVE — To assess the effect of simvastatin treatment on the risk of cardiovascular events
in nondiabetic patients with coronary heart disease (CHD) with and without the meta- bolic
syndrome, as defined by the National Cholesterol Education Program (NCEP) Adult ... Related articles - View as HTML - All 4 versions
PL Canner, CD Furberg, ML Terrin, ME McGovern - The American journal of …, 2005 - Elsevier The Coronary Drug Project, conducted during 1966 to 1974, was a randomized,
double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men with previous
myocardial infarction. 1 Among the 5 drug treatment regimens, only niacin significantly ... Cited by 111 - Related articles - All 12 versions
GG Schwartz, AG Olsson, M Szarek, WJ Sasiela - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—A total of 38% of patients (n = 1,161) met criteria for metabolic syndrome as defined
in this study and had a 19% incidence of a primary end point event (death, nonfatal myocardial
infarction, cardiac arrest, or recurrent unstable myocardial ischemia) during the 16-week ... Cited by 28 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org CA Geluk, FW Asselbergs, HL Hillege, SJL … - European heart …, 2005 - Eur Soc Cardiology Methods and results This substudy of the PREVEND Intervention Trial (a randomized,
placebo-controlled trial with a 2x2 factorial design) included 864 microalbuminuric subjects,
who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or ... Cited by 36 - Related articles - All 9 versions
- ►lipidgeneticsclinic.ca [PDF] P Deedwania, P Barter, R Carmena, JC Fruchart, SM … - The Lancet, 2006 - Elsevier The TNT study was a prospective, double blind, parallel-group trial done at 256 sites in 14 countries
between April, 1998, and August, 2004, with a median follow-up of 4·9 years. 10 001 patients
were enrolled aged 35–75 years with clinically evident coronary heart disease. Our ... Cited by 108 - Related articles - All 11 versions
VG Athyros, DP Mikhailidis, AA Papageorgiou, TP … - Metabolism, 2005 - Elsevier There are no prospective data on the effect of a multitargeted treatment approach on cardiovascular
disease (CVD) risk reduction in nondiabetic patients with metabolic syndrome (MetS).
Furthermore, the optimal hypolipidemic drug treatment in these patients remains ... Cited by 43 - Related articles - All 7 versions
CJ Girman, T Rhodes, M Mercuri, K Pyörälä, J … - The American journal of …, 2004 - Elsevier The metabolic syndrome, which is a set of lipid and nonlipid risk factors of metabolic origin linked
with insulin resistance, is believed to be associated with an elevated risk for cardiovascular
disease, but few have studied this association in prospective long-term cardiovascular ... Cited by 250 - Related articles - All 4 versions
SJ Robins, HB Rubins, FH Faas, EJ Schaefer, MB … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This intention-to-treat analysis, specified as a secondary
objective in VA-HIT, determined using Cox proportional hazards models the 5-year combined
incidence of nonfatal myocardial infarction, coronary heart disease (CHD) death, or stroke ... Cited by 153 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org AFH Stalenhoef, CM Ballantyne, C Sarti, J … - European heart …, 2005 - Eur Soc Cardiology Methods and results Patients with the metabolic syndrome with low-density lipoprotein cholesterol
(LDL-C) 3.36 mmol/L (130 mg/dL) and multiple risk factors conferring a 10-year coronary heart
disease risk score of >10% were randomized (2:2:1) to receive rosuvastatin 10 mg, ... Cited by 71 - Related articles - BL Direct - All 6 versions
